{"id":4186,"date":"2023-07-18T05:19:12","date_gmt":"2023-07-18T05:19:12","guid":{"rendered":"https:\/\/mpelembe.net\/?p=4186"},"modified":"2023-07-18T05:19:12","modified_gmt":"2023-07-18T05:19:12","slug":"alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023","status":"publish","type":"post","link":"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/","title":{"rendered":"ALZHEIMER’S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023"},"content":{"rendered":"

The data reported today by Eli Lilly from the TRAILBLAZER-ALZ 2 clinical trial of donanemab in early symptomatic Alzheimer’s disease demonstrate an important advancement in Alzheimer’s research and treatment. The full Phase 3 data was reported at the Alzheimer’s Association International Conference\u00ae (AAIC\u00ae) 2023, in Amsterdam, Netherlands, and online. The data were simultaneously published in the Journal of the American Medical Association. Continue reading<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The data reported today by Eli Lilly from the TRAILBLAZER-ALZ 2 clinical trial of donanemab in early symptomatic Alzheimer’s disease demonstrate an important advancementRead More…<\/a><\/p>\n","protected":false},"author":1,"featured_media":4187,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAowu7GVCw:productID":"","_crdt_document":"","activitypub_content_warning":"","activitypub_content_visibility":"","activitypub_max_image_attachments":3,"activitypub_interaction_policy_quote":"anyone","activitypub_status":"","footnotes":""},"categories":[21],"tags":[9181,5764,2437,2028,1714,9177,9180,5766,9176,980],"class_list":["post-4186","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-reasearch","tag-aaic","tag-alzheimers-association","tag-alzheimers-disease","tag-amsterdam","tag-clinical-trial","tag-donanemab","tag-eli-lilly","tag-eli-lilly-and-company","tag-monoclonal-antibodies","tag-netherlands"],"featured_image_src":"https:\/\/mpelembe.net\/wp-content\/uploads\/2023\/07\/AAIC23_Logo.jpg","blog_images":{"medium":"https:\/\/mpelembe.net\/wp-content\/uploads\/2023\/07\/AAIC23_Logo-300x128.jpg","large":"https:\/\/mpelembe.net\/wp-content\/uploads\/2023\/07\/AAIC23_Logo.jpg"},"ams_acf":[],"yoast_head":"\nALZHEIMER'S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023 - Mpelembe Network<\/title>\n<meta name=\"description\" content=\"The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ALZHEIMER'S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023 - Mpelembe Network\" \/>\n<meta property=\"og:description\" content=\"The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Mpelembe Network\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-18T05:19:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mpelembe.net\/wp-content\/uploads\/2023\/07\/AAIC23_Logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"170\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/mpelembe.net\\\/#\\\/schema\\\/person\\\/2421ebbf3150931b1066b10a196d7608\"},\"headline\":\"ALZHEIMER’S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023\",\"datePublished\":\"2023-07-18T05:19:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\\\/\"},\"wordCount\":71,\"image\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mpelembe.net\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/AAIC23_Logo.jpg\",\"keywords\":[\"AAIC\",\"Alzheimer's Association\",\"Alzheimer's disease\",\"Amsterdam\",\"Clinical trial\",\"Donanemab\",\"Eli Lilly\",\"Eli Lilly and Company\",\"Monoclonal antibodies\",\"Netherlands\"],\"articleSection\":[\"Reasearch\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\\\/\",\"url\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\\\/\",\"name\":\"ALZHEIMER'S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023 - Mpelembe Network\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mpelembe.net\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/AAIC23_Logo.jpg\",\"datePublished\":\"2023-07-18T05:19:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/#\\\/schema\\\/person\\\/2421ebbf3150931b1066b10a196d7608\"},\"description\":\"The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mpelembe.net\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/AAIC23_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mpelembe.net\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/AAIC23_Logo.jpg\",\"width\":400,\"height\":170,\"caption\":\"AAIC2023\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/mpelembe.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ALZHEIMER’S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mpelembe.net\\\/#website\",\"url\":\"https:\\\/\\\/mpelembe.net\\\/\",\"name\":\"Mpelembe Network\",\"description\":\"Collaboration Platform\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/mpelembe.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/mpelembe.net\\\/#\\\/schema\\\/person\\\/2421ebbf3150931b1066b10a196d7608\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c66a2765397adfb52418f6f2310640167a0af23ce662da1b68c8a0b8650de556?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c66a2765397adfb52418f6f2310640167a0af23ce662da1b68c8a0b8650de556?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c66a2765397adfb52418f6f2310640167a0af23ce662da1b68c8a0b8650de556?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/mpelembe.net\"],\"url\":\"https:\\\/\\\/mpelembe.net\\\/index.php\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ALZHEIMER'S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023 - Mpelembe Network","description":"The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/","og_locale":"en_US","og_type":"article","og_title":"ALZHEIMER'S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023 - Mpelembe Network","og_description":"The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias.","og_url":"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/","og_site_name":"Mpelembe Network","article_published_time":"2023-07-18T05:19:12+00:00","og_image":[{"width":400,"height":170,"url":"https:\/\/mpelembe.net\/wp-content\/uploads\/2023\/07\/AAIC23_Logo.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/#article","isPartOf":{"@id":"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/"},"author":{"name":"admin","@id":"https:\/\/mpelembe.net\/#\/schema\/person\/2421ebbf3150931b1066b10a196d7608"},"headline":"ALZHEIMER’S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023","datePublished":"2023-07-18T05:19:12+00:00","mainEntityOfPage":{"@id":"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/"},"wordCount":71,"image":{"@id":"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mpelembe.net\/wp-content\/uploads\/2023\/07\/AAIC23_Logo.jpg","keywords":["AAIC","Alzheimer's Association","Alzheimer's disease","Amsterdam","Clinical trial","Donanemab","Eli Lilly","Eli Lilly and Company","Monoclonal antibodies","Netherlands"],"articleSection":["Reasearch"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/","url":"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/","name":"ALZHEIMER'S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023 - Mpelembe Network","isPartOf":{"@id":"https:\/\/mpelembe.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/#primaryimage"},"image":{"@id":"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mpelembe.net\/wp-content\/uploads\/2023\/07\/AAIC23_Logo.jpg","datePublished":"2023-07-18T05:19:12+00:00","author":{"@id":"https:\/\/mpelembe.net\/#\/schema\/person\/2421ebbf3150931b1066b10a196d7608"},"description":"The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias.","breadcrumb":{"@id":"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/#primaryimage","url":"https:\/\/mpelembe.net\/wp-content\/uploads\/2023\/07\/AAIC23_Logo.jpg","contentUrl":"https:\/\/mpelembe.net\/wp-content\/uploads\/2023\/07\/AAIC23_Logo.jpg","width":400,"height":170,"caption":"AAIC2023"},{"@type":"BreadcrumbList","@id":"https:\/\/mpelembe.net\/index.php\/alzheimers-association-statement-on-donanemab-phase-3-data-reported-at-aaic-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/mpelembe.net\/"},{"@type":"ListItem","position":2,"name":"ALZHEIMER’S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023"}]},{"@type":"WebSite","@id":"https:\/\/mpelembe.net\/#website","url":"https:\/\/mpelembe.net\/","name":"Mpelembe Network","description":"Collaboration Platform","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mpelembe.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/mpelembe.net\/#\/schema\/person\/2421ebbf3150931b1066b10a196d7608","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/c66a2765397adfb52418f6f2310640167a0af23ce662da1b68c8a0b8650de556?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c66a2765397adfb52418f6f2310640167a0af23ce662da1b68c8a0b8650de556?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c66a2765397adfb52418f6f2310640167a0af23ce662da1b68c8a0b8650de556?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/mpelembe.net"],"url":"https:\/\/mpelembe.net\/index.php\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/posts\/4186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/comments?post=4186"}],"version-history":[{"count":1,"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/posts\/4186\/revisions"}],"predecessor-version":[{"id":4188,"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/posts\/4186\/revisions\/4188"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/media\/4187"}],"wp:attachment":[{"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/media?parent=4186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/categories?post=4186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mpelembe.net\/index.php\/wp-json\/wp\/v2\/tags?post=4186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}